Production of therapeutic quantities of 64Cu using a 12 MeV cyclotron

被引:128
作者
Obata, A [1 ]
Kasamatsu, S
McCarthy, DW
Welch, MJ
Saji, H
Yonekura, Y
Fujibayashi, Y
机构
[1] Fukui Med Univ, Biomed Imaging Res Ctr, Fukui 9101193, Japan
[2] Kyoto Univ, Grad Sch Pharmaceut Sci, Kyoto 6068151, Japan
[3] Fukui Med Univ, NKK Fukui Branch, Fukui 9101193, Japan
[4] Washington Univ, Med Ctr, Mallinckrodt Inst Radiol, St Louis, MO 63110 USA
关键词
Cu-64; cyclotron; tumor; therapy; PET;
D O I
10.1016/S0969-8051(03)00024-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Cu-64 is a useful radiotracer for positron emission tomography (PET) and a promising radiotherapy agent for the treatment of cancer. Recently, Cu-64-labeled radiopharmaceuticals were reported to be useful for internal radiation therapy as well as PET monitoring of tumors. Cu-64 was produced at the Fukui Medical University's cyclotron using twelve MeV proton irradiation and the Ni-64(p,n) Cu-64 nuclear reaction. A Ni-64 target was electroplated on a gold disk at a thickness of 50 to >100 mum. Electroplating was performed at 2.5 V, at currents between 5-15 mA, and was completed in 12-24 hr. The Ni-64 target was bombarded with a 50+/-3 muA proton current. After bombardment, Cu-64 was separated from the Ni-64 target and other contaminants using an anion exchange column. Target Ni-64 was recovered and re-used. The yield of Cu-64 was 0.6 to >3.0 mCi/muA*h, and averaged 1.983 mCi/muA*h. The radionuclidic purity of Cu-64 was over 99%. In this study, we obtained sufficient qualities and quantities of Cu-64 for therapeutic application and dose monitoring using PET using an ultra-small cyclotron. (C) 2003 Elsevier Inc. All rights reserved.
引用
收藏
页码:535 / 539
页数:5
相关论文
共 10 条
[1]  
Anderson CJ, 1998, J NUCL MED, V39, P1944
[2]  
ANDERSON CJ, 1992, J NUCL MED, V33, P1685
[3]   Radioimmunotherapy with a Cu-64-labeled monoclonal antibody: A comparison with Cu-67 [J].
Connett, JM ;
Anderson, CJ ;
Guo, LW ;
Schwarz, SW ;
Zinn, KR ;
Rogers, BE ;
Siegel, BA ;
Philpott, GW ;
Welch, MJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (13) :6814-6818
[4]  
DEHDASHTI F, 1997, J NUCL MED, V38, P103
[5]  
Lewis JS, 1999, CLIN CANCER RES, V5, P3608
[6]   Efficient production of high specific activity Cu-64 using a biomedical cyclotron [J].
McCarthy, DW ;
Shefer, RE ;
Klinkowstein, RE ;
Bass, LA ;
Margeneau, WH ;
Cutler, CS ;
Anderson, CJ ;
Welch, MJ .
NUCLEAR MEDICINE AND BIOLOGY, 1997, 24 (01) :35-43
[7]   Retention mechanism of hypoxia selective nuclear imaging/radiotherapeutic agent Cu-diacetyl-bis(N4-methylthiosemicarbazone) (Cu-ATSM) in tumor cells [J].
Obata, A ;
Yoshimi, E ;
Waki, A ;
Lewis, JS ;
Oyama, N ;
Welch, MJ ;
Saji, H ;
Yonekura, Y ;
Fujibayashi, Y .
ANNALS OF NUCLEAR MEDICINE, 2001, 15 (06) :499-504
[8]  
PHILPOTT GW, 1995, J NUCL MED, V36, P1818
[9]   EXCITATION-FUNCTIONS OF PROTON-INDUCED NUCLEAR-REACTIONS ON ENRICHED NI-61 AND NI-64 - POSSIBILITY OF PRODUCTION OF NO-CARRIER-ADDED CU-61 AND CU-64 AT A SMALL CYCLOTRON [J].
SZELECSENYI, F ;
BLESSING, G ;
QAIM, SM .
APPLIED RADIATION AND ISOTOPES, 1993, 44 (03) :575-580
[10]  
ZWEIT J, 1991, APPL RADIAT ISOTOPES, V42, P193, DOI 10.1016/0883-2889(91)90073-A